Date: Apr 28, 2014 Source: Business Wire (
click here to go to the source)
PASADENA, Calif.--(BUSINESS WIRE)--Neumedicines Inc., a privately held biotechnology company, announced today that their proposal to conduct a phase I clinical study of recombinant human interleukin-12 (rHuIL-12) for the treatment of traumatic wounds has been recommended for funding subject to negotiations by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP).
"We are extremely grateful for the DoD's funding recommendation, encouraged by the response of their scientific review, and excited about the scientific and clinical implications of this R&D. rHuIL-12 has great promise as a treatment for wound healing and infection"
Neumedicines' proposal, "Recombinant Interleukin-12, a Broad-Spectrum Biologic for the Treatment of Battle and Traumatic Wound Infections," was submitted in response to the Fiscal Year 2014 (FY14) Defense Medical Research and Development Program (DMRDP) Military Infectious Diseases Clinical Trial Award (MID-CTA), which is solicited for the Assistant Secretary of Defense for Health Affairs, Defense Health Program (DHP), by the U.S. Army Medical Research Acquisitions Activity (USAMRAA).
Interleukin-12 (IL-12) plays a central role in linking and regulating both innate (early nonspecific) and adaptive (late specific) immunity while also playing a critical role in hematopoietic cell-to-cell signaling. IL-12's role in cell-to-cell signaling of other adult stem cell populations, including those found in skin, is being investigated.
"We are extremely grateful for the DoD's funding recommendation, encouraged by the response of their scientific review, and excited about the scientific and clinical implications of this R&D. rHuIL-12 has great promise as a treatment for wound healing and infection," said Dr. Lena Basile, Neumedicines Founder and Chief Executive Officer.
Under the trade name HemaMax™, Neumedicines is also developing rHuIL-12 as a treatment for the hematopoietic syndrome of acute radiation syndrome (HSARS) and as a treatment for various indications in oncology, including cutaneous T cell lymphoma (CTCL), acute myeloid leukemia (AML), melanoma, solid tumors, various immunotherapy applications, and hematopoietic support.
About HemaMax™ (rHuIL-12)
HemaMax™ (rHuIL-12) holds considerable value and promise playing a central role in linking and regulating both innate (early nonspecific) and adaptive (late specific) immunity while also playing a critical role in hematopoietic cell-to-cell signaling. In addition to HSARS, HemaMax™ is also being developed for various indications in oncology, including cutaneous T cell lymphoma (CTCL), acute myeloid leukemia (AML), melanoma, solid tumors, various immunotherapy applications, and hematopoietic support.
About Neumedicines Inc.
Neumedicines Inc., a California corporation, is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches for the treatment of various clinical indications that address unmet clinical and societal needs in the fields of oncology, hematology, and immunology. The company operates from its headquarters and laboratories in Pasadena, California.
For more information visit: http://www.neumedicines.com
Follow Neumedicines on Twitter: @Neumedicines
Follow Neumedicines on LinkedIn: http://www.linkedin.com/company/neumedicines
About Defense Medical Research and Development Program (DMRDP)
The Defense Medical Research and Development Program (DMRDP) is a core research program of the Department of Defense (DoD) within the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]). The DMRDP serves as the focal point for Defense Health Program (DHP) execution of research, development, test, and evaluation (RDT&E) funds. The goal of the DMRDP is to advance the state of medical science in those areas of most pressing need and relevance to today's battlefield experience. The objectives of the DMRDP are to discover and explore innovative approaches to protect, support, and advance the health and welfare of military personnel, families, and communities; to accelerate the transition of medical technologies into deployed products; and to accelerate the translation of advances in knowledge into new standards of care for injury prevention, treatment of casualties, rehabilitation, and training systems that can be applied in theater, in the clinical facilities of the Military Health System, or in civilian health care facilities.
For more information visit: http://cdmrp.army.mil/dmrdp/
This press release contains certain forward-looking statements relating to our business. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs. There can be no assurance that any product in Neumedicines pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
Contacts
Corporate/Investor Contact:
Neumedicines Inc.
David Morash, CFO
626-844-3800
dmorash@neumedicines.com
or
Media Contact:
Neumedicines Inc.
Richard Leon, Media Relations
626-844-3800
leon@neumedicines.com
